肌少症、临床数据与2-[18F]FDG PET/CT对早期食管腺癌预后的影响
本研究纳入145例接受手术治疗的早期食管腺癌患者,利用 staging 2-[18F]FDG PET/CT 测量骨骼肌指数(SMI)以定义肌少症,并记录肿瘤代谢参数SUV和SUL。多变量Cox回归显示手术N分期(p=0.025)和肌少症(p=0.022)是OS和RFS的独立不良预后因素;将影像衍生的营养评估与临床参数结合可改善预后预测能力,而肿瘤代谢参数未提供额外预后价值。
要点
- 基线30%的早期食管腺癌手术患者存在肌少症。
- 肌少症和手术N分期是OS和RFS的独立不良预后因素。
- 影像衍生肌少症状态联合临床数据可改善预后预测,肿瘤代谢参数无额外价值。
核心结论
- 将影像衍生的肌少症状态与标准临床数据结合,可改善早期食管腺癌手术患者的OS和RFS预后预测。
- 肿瘤代谢参数(SUV、SUL)未显示额外预后价值。
研究设计与样本
- 回顾性纳入145例早期、接受手术治疗的食管腺癌患者,且具备治疗前2-[18F]FDG PET/CT。
- 在PET/CT的CT组分L3层面测量骨骼肌指数(SMI),肌少症定义为女性SMI<34.4cm2/m2、男性<45.4cm2/m2。
- 记录肿瘤SUV和SUL,采用Cox比例风险分析评估预后因素。
主要发现
- 基线时30%的患者存在肌少症。
- 单变量Cox分析中,ECOG、手术T和N分期、淋巴血管侵犯(LVI)、阳性淋巴结和肌少症与RFS和OS显著相关。
- 多变量Cox回归中,手术N分期(p=0.025)和肌少症(p=0.022)是OS和RFS的独立不良预后因素。
- 联合临床参数与影像衍生营养评估(而非肿瘤代谢参数)改善了OS和RFS的预测能力。
关键数值与推荐
- 肌少症定义:女性SMI<34.4cm2/m2,男性SMI<45.4cm2/m2。
- 多变量分析中手术N分期p=0.025、肌少症p=0.022为OS和RFS的显著预后因素。
临床怎么用
- 对早期食管腺癌手术患者,可利用 staging PET/CT 的CT组分评估L3层面SMI以识别肌少症。
- 将肌少症状态纳入临床预后评估,可能改善OS和RFS的风险分层。
- 肿瘤SUV和SUL在本研究中未显示额外预后价值,不应单独用于预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the prognostic value of sarcopenia measurements done on staging 2-[18F] FDG PET/CT together with metabolic activity of the tumor in patients with adenocarcinoma esophagogastric cancer with surgical treatment. METHODS: Patients with early-stage, surgically treated esophageal adenocarcinoma and available pre-treatment 2-[18F] FDG PET/CT were included. The standard uptake value (SUV) and SUV normalized by lean body mass (SUL) were recorded. Skeletal muscle index (SMI) was measured at the L3 level on the CT component of the PET/CT. Sarcopenia was defined as SMI < 34.4cm2/m2 in women and < 45.4cm2/m2 in men. RESULTS: Of the included 145 patients. 30% were sarcopenic at baseline. On the univariable Cox proportional hazards analysis, ECOG, surgical T and N staging, lymphovascular invasion (LVI) positive lymph nodes, and sarcopenia were significant prognostic factors concerning RFS and OS. On multivariable Cox regression analysis, surgical N staging (p = 0.025) and sarcopenia (p = 0.022) remained significant poor prognostic factors for OS and RFS. Combining the clinical parameters with the imaging-derived nutritional evaluation of the patient but not metabolic parameters of the tumor showed improved predictive ability for OS and RFS. CONCLUSION: Combining the patients' imaging-derived sarcopenic status with standard clinical data, but not metabolic parameters, offered an overall improved prognostic value concerning OS and RFS.
引用
- Anconina R, Ortega C, Metser U, et al. Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34491404. doi:10.1007/s00259-021-05514-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。